Earnings History Data for VYNE Therapeutics (VYNE) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

VYNE Therapeutics

VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company's product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo Therapeutics Inc., is based in Bridgewater, New Jersey.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
07-11-2024	PM		VYNE	VYNE Therapeutics	48.00	-0.29	-0.24	0.00	VYNE Therapeutics GAAP EPS of -$0.29, revenue of $0.1M [11/7/2024 9:15 AM]	3.17	0.04 (1.28%)	3.25	0.12 (3.83%)	1.57 - 4.48	179,046	140,000	2,918
VYNE Therapeutics GAAP EPS of -$0.29, revenue of $0.1M [11/7/2024 9:15 AM] VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [2024-11-07 08:00AM]
14-08-2024	PM		VYNE	VYNE Therapeutics	24.00	-0.22	-0.19	0.00		1.74	0.03 (1.46%)	0.0	0.0 (0.00%)	1.57 - 6.37	98,224	60,000	0

29-02-2024	PM		VYNE	VYNE Therapeutics	33.00	-0.20	-0.50	0.00		2.22	-0.11 (-4.72%)	0.0	0.0 (0.00%)	1.67 - 8.73	78,516	70,000	0

13-11-2023	PM		VYNE	VYNE Therapeutics	10.00	-1.85	-0.76	0.00	VYNE Therapeutics GAAP EPS of -$2.01, revenue of $0.1M [11/13/2023 8:43 AM]	3.42	-0.09 (-2.56%)	3.29	-0.22 (-6.27%)	1.99 - 8.73	116,762	2,120,000	873
VYNE Therapeutics GAAP EPS of -$2.01, revenue of $0.1M [11/13/2023 8:43 AM]
09-03-2023	AH		VYNE	VYNE Therapeutics	10.00	-2.60	-3.24	0.00	VYNE Therapeutics GAAP EPS of -$2.60 [3/9/2023 5:02 PM]	2.55	-0.45 (-14.93%)	2.93	-0.07 (-2.33%)	1.99 - 14.22	16,695	10,000	886
VYNE Therapeutics GAAP EPS of -$2.60 [3/9/2023 5:02 PM]
12-08-2022	PM		VYNE	VYNE Therapeutics Inc.	27.53	-0.14	-0.17	-0.39	VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M [8/12/2022 8:24 AM]	0.3160	0.01 (3.95%)	0.29	-0.01 (-4.61%)	0.26 - 2.44	577,137	770,000	38,371
VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M [8/12/2022 8:24 AM] VYNE Therapeutics Reports Second Quarter 2022 Financial Results [Aug-12-22 08:00AM]
10-11-2021	PM	7:30 AM ET (Nov 10)	VYNE	VYNE Therapeutics Inc.	70.57	-0.41	-0.33	-0.60	VYNE Therapeutics EPS misses by $0.04, misses on revenue [11/10/2021 7:36 AM]	1.31	-0.05 (-3.68%)	1.34	-0.02 (-1.47%)	1.08 - 13.20	527,538	600,000	31,476
VYNE Therapeutics Q3 2021 Earnings Preview [11/9/2021 11:53 AM] VYNE Therapeutics EPS misses by $0.04, misses on revenue [11/10/2021 7:36 AM] VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update [Nov-10-21 07:30AM]
12-08-2021	PM	7:00 AM ET (Aug 12)	VYNE	VYNE Therapeutics Inc.	140.80	-0.39	-0.36	-4.84	VYNE Therapeutics EPS in-line, misses on revenue [8/12/2021 7:34 AM]	1.99	-0.90 (-31.14%)	2.02	0.03 (1.51%)	1.97 - 13.20	4,842,227	420,000	1,000
VYNE Therapeutics EPS in-line, misses on revenue [8/12/2021 7:34 AM] VYNE Therapeutics falls 13% after BET inhibitor licensing deal with In4derm [8/12/2021 8:00 AM] Are Institutions Heavily Invested In VYNE Therapeutics Inc.'s (NASDAQ:VYNE) Shares? [Aug-11-21 08:43AM] VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited [Aug-12-21 07:00AM] VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases [Aug-12-21 07:30AM]
06-05-2021	PM	7:00 AM ET (May 6)	VYNE	VYNE Therapeutics Inc.	237.92	-0.42	-0.47	-3.80	VYNE Therapeutics EPS beats by $0.03, misses on revenue [5/6/2021 7:06 AM]	3.56	-0.96 (-21.24%)	4.12	-0.40 (-8.85%)	3.50 - 13.20	4,387,647	690,000	98,754
VYNE Therapeutics EPS beats by $0.03, misses on revenue [5/6/2021 7:06 AM] VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update [May-06-21 07:00AM]
04-03-2021	PM	7:00 AM ET (Mar 4)	VYNE	VYNE Therapeutics Inc.	373.66	-0.55	-0.54	-3.56	VYNE Therapeutics EPS beats by $0.08, misses on revenue [3/4/2021 7:53 AM]	6.66	-0.74 (-10.07%)	7.15	-0.25 (-3.38%)	4.00 - 17.96	2,062,300	1,985,835	61,726
VYNE Therapeutics EPS beats by $0.08, misses on revenue [3/4/2021 7:53 AM] VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update [Mar-04-21 07:00AM] VYNE Therapeutics Inc to Host Earnings Call [Mar-04-21 06:30AM]
05-11-2020	PM		VYNE	VYNE Therapeutics Inc.	298.49	-0.60	-0.17	-0.70	VYNE Therapeutics EPS beats by $0.02, beats on revenue [11/5/2020 7:25 AM]	1.77	0.05 (2.91%)	1.77	0.0 (0.00%)	1.00 - 7.48	1,506,128	1,330,252	700